Medusa 19 is a global distribution company bringing mass test solutions to market, in response to the COVID-19 pandemic. Our products and services offer fast, non-intrusive, reliable, scalable and effective testing solutions for businesses. We are already supporting a wide range of businesses and organisations, ensuring they have a regular testing regime that works for them, providing employee safety and business continuity.

Although the roll-out of the vaccine is very positive, businesses are increasingly realising that there is a need to “normalise” COVID-19 testing in their workplace in conjunction with the vaccination.

Founded in early 2020 to supply scalable COVID-19 testing solutions to help businesses and organisations rebuild confidence and trust with employees and customers. Our Co-Founders Richard Hughes and Mahmud Kamani – Founders of Boohoo, have extensive experience in e-commerce, supply chains, marketing and e-fulfilment, enabling Medusa 19 to play a key role in ‘Rebuilding Confidence’ in businesses and the economy.

Medusa 19 Logo

Rapid Saliva Protein Test

The Rapid Saliva Protein Test (RSPT), from Medusa 19, provides results on the spot in 15 minutes. It is a lateral flow saliva test to indicate the immune response to infection particularly in patients whom do not know they have an active SARS-CoV-2 infection and have no specific symptoms.

The Rapid Saliva Protein Test (RSPT) is a simple, non-invasive, on the spot test indicating the immune response to infection from SARS-CoV-2, the virus underlying COVID-19.

It is a lateral flow test requiring a simple saliva sample, a comfortable and non-invasive collection process, providing rapid results within 15 minutes.

Developed in the UK and Spain, the test indicates a user’s immune response to SARS-CoV-2.

Relative sensitivity of 92%, relative specificity of 98% and 97% accuracy.

Avacta Life Sciences Antigen Test – COMING SOON

Medusa 19 has entered into a distribution agreement with Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, for its COVID-19 rapid antigen test that is currently under development. 

This agreement provides Medusa 19 with exclusive distribution rights to consumers and non-exclusive distribution rights to businesses.

The test is being developed to indicate whether an individual has the COVID-19 infection and is intended to provide a result within minutes.

See more on the Avacta site or via our news section.

 

Saturn Pass – COMING SOON

Medusa 19 is also working with Saturn Pass, who are developing a Digital Health Passport App for iOS and Android.  This will include:-

  • Full Facial recognition and Identity Document Scanning
  • Unique Home and Workplace test verification capability using Computer Vision
  • Legal declaration with approved e-signing
  • Patent Pending